Diabetic Peripheral Neuropathic Pain
📧 Sign up to get email alerts when something new happens for Diabetic Peripheral Neuropathic Pain.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy [Phase 3]
Phase 3 evaluation of Suzetrigine for pain associated with diabetic peripheral neuropathy is ongoing, focusing on efficacy and safety.
-
FDA approval · 2026-04-09FDA Approved: DULOXETINE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approves a supplemental application for duloxetine hydrochloride as a generic product from Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain [Phase 4]
A Phase 4 clinical trial is evaluating the efficacy and safety of mirogabalin for diabetic peripheral neuropathic pain, with recruitment ong…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Using Lymphovenous Bypass to Alleviate Diabetic Peripheral Neuropathy [NA]
An ongoing National Taiwan University Hospital study is evaluating lymphovenous bypass as a treatment to alleviate diabetic peripheral neuro…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) [Phase 2]
This update reports the completion of a Phase 2 dose-ranging study in patients with Diabetic Peripheral Neuropathic Pain sponsored by Lexico…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-07-01FDA Approved: PREGABALIN CAPSULES, CV — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for Pregabalin Capsules, CV from Cipla USA Inc., under ANDA to market this generic pregabalin capsul…
-
FDA approval · 2025-03-28FDA Approved: DULOXETINE DELAYED-RELEASE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical's supplemental ANDA for a duloxetine hydrochloride delayed-release product, making a generic du…
-
CLINICAL_TRIALS approval · 2025-01-10Clinical Trial Update: Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Clinical trial update indicates that duloxetine, sponsored by Eli Lilly, has been approved for marketing in relation to a compassionate-use …
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05). [Phase 2]
A Phase 2 study (NP05) evaluating LY3857210 in diabetic peripheral neuropathic pain has completed, with results posted in August 2024.
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of HSK16149 Capsule in Chinese patients with diabetic peripheral neuropathic pain …
-
FDA approval · 2023-12-19FDA Approved: DULOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for duloxetine hydrochloride from Aurobindo Pharma Limited, granting regulatory clearance for a gene…
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain [Phase 2]
Phase 2 trial update for LY3526318 in diabetic peripheral neuropathic pain has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain [Phase 2]
Phase 2 trial update for LY3556050 in diabetic peripheral neuropathic pain; study terminated with results posted.
-
FDA approval · 2023-08-18FDA Approved: DRIZALMA SPRINKLE — Supplemental Application (SUN PHARMACEUTICAL INDUSTRIES, INC.)
The FDA approved Sun Pharmaceutical's supplemental NDA for Drizalma Sprinkle (duloxetine), adding a sprinkle-form formulation and related la…
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain [Phase 2]
Phase 2 trial results for ETX-018810 in diabetic peripheral neuropathic pain and diabetic peripheral neuropathy have been posted following c…
-
FDA approval · 2023-05-02FDA Approved: DULOXETINE — Supplemental Application (Solco Healthcare US, LLC)
The FDA approved a supplemental application for duloxetine submitted by Solco Healthcare US, LLC (ANDA206653), authorizing a change related …
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN) [Phase 2]
Phase 2 clinical trial evaluating NYX-2925 for efficacy and safety in neuropathic pain due to diabetic peripheral neuropathy has completed w…
-
CLINICAL_TRIALS trial_result · 2023-03-13Clinical Trial Update: Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating sublingual water-soluble CBD/PEA for diabetic peripheral neuropathic pain; status currently UNKNO…
-
CLINICAL_TRIALS trial_result · 2022-10-24Clinical Trial Update: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain [Phase 3]
Phase 3 multicenter trial of DS-5565 in Chinese patients with diabetic peripheral neuropathic pain has completed.
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain [Phase 2]
Phase 2 trial update for LY3016859 in diabetic peripheral neuropathic pain has completed with results posted.
-
FDA approval · 2022-07-29FDA Approved: DULOXETINE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for duloxetine filed by Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2021-07-23FDA Approved: DRIZALMA SPRINKLE — Supplemental Application (SUN PHARMACEUTICAL INDUSTRIES, INC.)
The FDA approved a supplemental application for Drizalma Sprinkle, a duloxetine product, expanding the label to include a sprinkle-form dosa…
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet [Phase 2]
Phase 2 clinical trial investigating cannabidiol for diabetic peripheral neuropathic pain.
-
FDA approval · 2020-12-30FDA Approved: DULOXETINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' supplemental application for duloxetine (ANDA204343), enabling the continued marketing of the gener…
-
CLINICAL_TRIALS trial_result · 2020-12-01Clinical Trial Update: To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain [Phase 2, Phase 3]
A clinical trial update for HSK16149 capsule assessing efficacy and safety in diabetic peripheral neuropathic pain in Chinese patients (Phas…